|
The rapid rate of breakthroughs in immuno-oncology (IO) continues to disrupt diagnostic processes and workflows in cancer care. As more patients with different types of cancers are treated with immune checkpoint inhibitor therapy, pathologists and laboratory professionals need to work closely with oncologists and other cancer clinicians to optimize IO biomarker testing and ensure that patients are treated with the right agents. This live 1.5-hour CME multidisciplinary, interactive panel discussion will highlight practical ways to overcome barriers around IO biomarker testing, communication among members of the multidisciplinary cancer care team, and the use of immune checkpoint inhibitor therapy to improve patient care.
0 Comments
Your comment will be posted after it is approved.
Leave a Reply. |
Author@DrJosephKim Sign up to receive updates:
|